COMPASS Pathways plc

NASDAQ:CMPS

Medical - Care Facilities

Healthcare
$8.12 +0.16%

+$0.02 today

Market cap
$1.15B
Beta
2.51
P/E (TTM)
-7.4
EPS (TTM)
-$1.63
52W Low $2.25High $14.76

Volume 2.35M

Average 4.09M

CMPS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

COMPASS Pathways plcNASDAQ: CMPS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $26.44M fell 14.4% year over year, behind the -12.0% change in trailing-twelve-month research & development. Sequentially, it fell 11.6% from the prior quarter. Over 3 fiscal years it compounded at +22.1% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -14.4% toward the trailing-twelve-month pace of -12.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$26.44M-11.6% QoQ
Last fiscal yearDec 2025
$118.44M-0.5% YoY
LTMMar 2026
$110.07M-12.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.4%——
1 year-0.5%——
3-year CAGR+22.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
118.44M USD
Year-over-year change
-0.5%
4-year CAGR
+28.1%

Research & Development vs competitors

How CMPS compares with its peers on the latest reported figures

  • CMPS's LTM Mar 2026 research & development of $110.07M is the 8th highest of the 11 companies compared; the peer median is $196.42M.
  • Its year-over-year change of -12.0% is the lowest of 10, against a peer median of +52.6%.
  • Over three fiscal years its annual growth of +22.1% compares with a peer median of +31.2%.
CMPS Competitors Peer median
Research & Development for CMPS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NERVMinerva Neurosciences, Inc.LTM Jun 2026$5.27B +80515.8%-26.7%—
DNLIDenali Therapeutics Inc.LTM Jun 2026$400.72M -3.9%+5.3%11118.8%
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$319.46M -7.3%-3.1%26.6%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$289.11M +17.6%+19.9%—
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$220.87M +52.6%+38.8%23.0%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$171.97M +136.8%+73.1%—
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$169.81M +60.3%+48.2%—
CMPSCOMPASS Pathways plcLTM Mar 2026$110.07M -12.0%+22.1%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.93M +58.7%+118.3%539.7%
GHRSGH Research PLCLTM Mar 2026$43.27M +26.5%+23.7%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$28.47M —+131.7%—
Peer median (excluding CMPS) $196.42M+52.6%+31.2%283.1%

Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development44.03M65.05M87.52M119.04M118.44M
Selling, General & Admin39.19M45.35M49.4M59.17M60.6M
Operating Expenses83.22M110.4M136.92M178.21M179.04M
Depreciation & Amortization175K330K242K233K216K
EBITDA(71.37M)(90.77M)(115.24M)(148.82M)(285.6M)
EBITDA Margin—————
Operating Income(83.22M)(110.4M)(136.92M)(178.21M)(179.04M)
Operating Margin—————
Interest Income004.62M8.27M7.18M
Interest Expense002.2M4.48M4.52M
Other Income / Expenses11.68M19.31M19.24M24.68M(111.3M)
Income Before Tax(71.54M)(91.1M)(117.68M)(153.53M)(290.34M)
Pre-Tax Margin—————
Income Tax Expense199K408K780K1.59M(2.47M)
Net Income(71.74M)(91.51M)(118.46M)(155.12M)(287.86M)
Net Margin—————
EPS (Basic)(1.79)(2.16)(2.32)(2.30)(3.08)
EPS (Diluted)(1.79)(2.16)(2.32)(2.30)(3.08)
Weighted Avg Shares40M42.44M51.03M67.48M93.5M
Weighted Avg Shares (Diluted)40M42.44M51.03M67.48M93.5M

COMPASS Pathways plc

NASDAQ:CMPS

Intrinsic Alpha fair value

Locked

Current Price

$8.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.